GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00074113 | Thyroid | ATC | axon guidance | 96/6293 | 227/18723 | 3.74e-03 | 1.63e-02 | 96 |
GO:004866016 | Thyroid | ATC | regulation of smooth muscle cell proliferation | 78/6293 | 180/18723 | 4.00e-03 | 1.73e-02 | 78 |
GO:00063031 | Thyroid | ATC | double-strand break repair via nonhomologous end joining | 33/6293 | 66/18723 | 4.27e-03 | 1.80e-02 | 33 |
GO:000717512 | Thyroid | ATC | negative regulation of epidermal growth factor-activated receptor activity | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:004314411 | Thyroid | ATC | sno(s)RNA processing | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:007148115 | Thyroid | ATC | cellular response to X-ray | 10/6293 | 14/18723 | 4.31e-03 | 1.80e-02 | 10 |
GO:001607411 | Thyroid | ATC | sno(s)RNA metabolic process | 11/6293 | 16/18723 | 4.33e-03 | 1.80e-02 | 11 |
GO:00974853 | Thyroid | ATC | neuron projection guidance | 96/6293 | 228/18723 | 4.36e-03 | 1.81e-02 | 96 |
GO:00434333 | Thyroid | ATC | negative regulation of DNA-binding transcription factor activity | 79/6293 | 185/18723 | 5.96e-03 | 2.40e-02 | 79 |
GO:00315707 | Thyroid | ATC | DNA integrity checkpoint | 55/6293 | 123/18723 | 6.64e-03 | 2.65e-02 | 55 |
GO:199082318 | Thyroid | ATC | response to leukemia inhibitory factor | 44/6293 | 95/18723 | 6.74e-03 | 2.68e-02 | 44 |
GO:003239216 | Thyroid | ATC | DNA geometric change | 42/6293 | 90/18723 | 6.81e-03 | 2.70e-02 | 42 |
GO:000283213 | Thyroid | ATC | negative regulation of response to biotic stimulus | 49/6293 | 108/18723 | 7.19e-03 | 2.84e-02 | 49 |
GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
GO:00311453 | Thyroid | ATC | anaphase-promoting complex-dependent catabolic process | 13/6293 | 21/18723 | 7.34e-03 | 2.87e-02 | 13 |
GO:0061081 | Thyroid | ATC | positive regulation of myeloid leukocyte cytokine production involved in immune response | 13/6293 | 21/18723 | 7.34e-03 | 2.87e-02 | 13 |
GO:00507305 | Thyroid | ATC | regulation of peptidyl-tyrosine phosphorylation | 108/6293 | 264/18723 | 7.50e-03 | 2.93e-02 | 108 |
GO:00022448 | Thyroid | ATC | hematopoietic progenitor cell differentiation | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
GO:00069721 | Thyroid | ATC | hyperosmotic response | 16/6293 | 28/18723 | 8.86e-03 | 3.36e-02 | 16 |
GO:00323292 | Thyroid | ATC | serine transport | 8/6293 | 11/18723 | 9.31e-03 | 3.44e-02 | 8 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa05133 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa051331 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C5 | SNV | Missense_Mutation | | c.4015G>C | p.Glu1339Gln | p.E1339Q | P01031 | protein_coding | tolerated(0.2) | probably_damaging(0.946) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
C5 | SNV | Missense_Mutation | | c.759N>T | p.Arg253Ser | p.R253S | P01031 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
C5 | SNV | Missense_Mutation | | c.2762N>G | p.Glu921Gly | p.E921G | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.655) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
C5 | SNV | Missense_Mutation | rs758293412 | c.3422G>A | p.Ser1141Asn | p.S1141N | P01031 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
C5 | SNV | Missense_Mutation | | c.1086N>A | p.Phe362Leu | p.F362L | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.73) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | | c.1118T>C | p.Val373Ala | p.V373A | P01031 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.4517N>T | p.Thr1506Ile | p.T1506I | P01031 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | rs369245774 | c.2017N>A | p.Leu673Ile | p.L673I | P01031 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.711N>A | p.Phe237Leu | p.F237L | P01031 | protein_coding | deleterious(0.01) | possibly_damaging(0.6) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.1643N>A | p.Gly548Glu | p.G548E | P01031 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | eculizumab | ECULIZUMAB | 24521109 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | LFG-316 | TESIDOLUMAB | 24860651 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | IFX-1 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1201828 | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2107979 | PEXELIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | SAND-5 | | 22990692 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | Ravulizumab | RAVULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | NNC-0151-0000-0000 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ECULIZUMAB | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ARC-1905 | AVACINCAPTAD PEGOL SODIUM | |